JP2010502425A - 膜を評価するシステム及び方法並びに膜濾過装置 - Google Patents
膜を評価するシステム及び方法並びに膜濾過装置 Download PDFInfo
- Publication number
- JP2010502425A JP2010502425A JP2009526858A JP2009526858A JP2010502425A JP 2010502425 A JP2010502425 A JP 2010502425A JP 2009526858 A JP2009526858 A JP 2009526858A JP 2009526858 A JP2009526858 A JP 2009526858A JP 2010502425 A JP2010502425 A JP 2010502425A
- Authority
- JP
- Japan
- Prior art keywords
- molecular weight
- large molecular
- weight marker
- membrane
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims description 30
- 238000011156 evaluation Methods 0.000 title claims description 13
- 238000005374 membrane filtration Methods 0.000 title description 7
- 239000003550 marker Substances 0.000 claims abstract description 96
- 238000001914 filtration Methods 0.000 claims abstract description 36
- 238000005259 measurement Methods 0.000 claims abstract description 8
- 230000029142 excretion Effects 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 51
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 239000012510 hollow fiber Substances 0.000 claims description 38
- 239000004094 surface-active agent Substances 0.000 claims description 35
- 102000009843 Thyroglobulin Human genes 0.000 claims description 28
- 108010034949 Thyroglobulin Proteins 0.000 claims description 28
- 229960002175 thyroglobulin Drugs 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 21
- 230000014759 maintenance of location Effects 0.000 claims description 19
- 102000000546 Apoferritins Human genes 0.000 claims description 16
- 108010002084 Apoferritins Proteins 0.000 claims description 16
- 241000701806 Human papillomavirus Species 0.000 claims description 15
- 239000012527 feed solution Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 6
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000001593 sorbitan monooleate Substances 0.000 claims description 5
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 5
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- -1 monoclonal antibody Proteins 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 239000012466 permeate Substances 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 239000011148 porous material Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920003081 Povidone K 30 Polymers 0.000 description 5
- 239000012465 retentate Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229960002566 papillomavirus vaccine Drugs 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000001612 separation test Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000010874 maintenance of protein location Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D65/00—Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
- B01D65/10—Testing of membranes or membrane apparatus; Detecting or repairing leaks
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82393106P | 2006-08-30 | 2006-08-30 | |
| PCT/US2007/076944 WO2008027861A1 (en) | 2006-08-30 | 2007-08-28 | System and method for characterizing membranes and membrane filtration devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502425A true JP2010502425A (ja) | 2010-01-28 |
| JP2010502425A5 JP2010502425A5 (enExample) | 2011-09-29 |
Family
ID=38669007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526858A Pending JP2010502425A (ja) | 2006-08-30 | 2007-08-28 | 膜を評価するシステム及び方法並びに膜濾過装置 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100288029A1 (enExample) |
| EP (1) | EP2069054A1 (enExample) |
| JP (1) | JP2010502425A (enExample) |
| WO (1) | WO2008027861A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745226B2 (en) | 2005-04-06 | 2010-06-29 | Quest Diagnostics Investments Incorporated | Methods for detecting vitamin D metabolites |
| US7972868B2 (en) | 2007-11-28 | 2011-07-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry |
| US8030084B2 (en) | 2007-12-06 | 2011-10-04 | Quest Diagnostics Investments Incorporated | Thyroglobulin quantitation by mass spectrometry |
| US7977117B2 (en) | 2009-12-03 | 2011-07-12 | Quest Diagnostics Investments Incorprated | Vitamin D metabolite determination utilizing mass spectrometry following derivatization |
| JP6113504B2 (ja) | 2009-12-11 | 2017-04-12 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | 非誘導体化非代謝化ビタミンｄの質量分析法による決定 |
| WO2011072152A1 (en) | 2009-12-11 | 2011-06-16 | Quest Diagnostics Investments Incorporated | Mass spectrometry of steroidal compounds in multiplex samples |
| CN104797715A (zh) | 2012-09-20 | 2015-07-22 | 奎斯特诊断投资公司 | 通过质谱法定量甲状腺球蛋白 |
| WO2020205696A1 (en) * | 2019-03-29 | 2020-10-08 | Rensselaer Polytechnic Institute | Assay for filtration of suspended particles in microporous membranes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01254204A (ja) * | 1988-04-01 | 1989-10-11 | Asahi Chem Ind Co Ltd | ウイルス除去方法 |
| JP2004099619A (ja) * | 1995-09-18 | 2004-04-02 | United States Army Medical Research Material Command (Usamrmc) | 非共有結合的に複合体を形成した、多価プロテオソームサブユニットワクチンの産生のための改善された方法 |
| JP2005523801A (ja) * | 2002-03-28 | 2005-08-11 | ナルコ カンパニー | 膜分離プロセスのモニタリングシステム |
| JP2005237755A (ja) * | 2004-02-27 | 2005-09-08 | Asahi Kasei Medical Co Ltd | 血液透析器 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5549386A (en) * | 1985-02-05 | 1986-08-26 | Synergen Biologicals Inc. | Metalloproteinase inhibitor sequence recombinant vector system for using same and recombinant dna for the manufactureof same |
| US4713975A (en) * | 1986-05-30 | 1987-12-22 | The Dow Chemical Company | Dense star polymers for calibrating/characterizing sub-micron apertures |
| US5968479A (en) * | 1995-01-30 | 1999-10-19 | Daiichi Pure Chemicals Co., Ltd. | Diagnostic marker |
| ZA982950B (en) * | 1997-04-08 | 1998-10-19 | Merck & Co Inc | Stabilized human papillomavirus formulations |
| PL347472A1 (en) * | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| GB0100513D0 (en) * | 2001-01-09 | 2001-02-21 | Smithkline Beecham Plc | Process |
-
2007
- 2007-08-28 US US12/377,936 patent/US20100288029A1/en not_active Abandoned
- 2007-08-28 WO PCT/US2007/076944 patent/WO2008027861A1/en not_active Ceased
- 2007-08-28 EP EP07814486A patent/EP2069054A1/en not_active Withdrawn
- 2007-08-28 JP JP2009526858A patent/JP2010502425A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01254204A (ja) * | 1988-04-01 | 1989-10-11 | Asahi Chem Ind Co Ltd | ウイルス除去方法 |
| JP2004099619A (ja) * | 1995-09-18 | 2004-04-02 | United States Army Medical Research Material Command (Usamrmc) | 非共有結合的に複合体を形成した、多価プロテオソームサブユニットワクチンの産生のための改善された方法 |
| JP2005523801A (ja) * | 2002-03-28 | 2005-08-11 | ナルコ カンパニー | 膜分離プロセスのモニタリングシステム |
| JP2005237755A (ja) * | 2004-02-27 | 2005-09-08 | Asahi Kasei Medical Co Ltd | 血液透析器 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100288029A1 (en) | 2010-11-18 |
| WO2008027861A1 (en) | 2008-03-06 |
| EP2069054A1 (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502425A (ja) | 膜を評価するシステム及び方法並びに膜濾過装置 | |
| JP3828143B2 (ja) | 改良された接線フロー濾過法および装置 | |
| Charcosset | Membrane processes in biotechnology and pharmaceutics | |
| TWI632156B (zh) | 用於自一蛋白質溶液的連續緩衝或介質交換的超過濾單元 | |
| Madsen et al. | Single pass tangential flow filtration: Critical operational variables, fouling, and main current applications | |
| EP3710141B1 (en) | Continuous diafiltration by means of tank cycling | |
| Schwartz et al. | Introduction to tangential flow filtration for laboratory and process development applications | |
| JP2003512594A (ja) | 生体物質の精製 | |
| TW200932330A (en) | Protein purification method | |
| US20060025579A1 (en) | Process for extraction of biological material | |
| Syedain et al. | Protein fouling of virus filtration membranes: Effects of membrane orientation and operating conditions | |
| Phillips et al. | Desalting, concentration, and buffer exchange by dialysis and ultrafiltration | |
| Shao et al. | Optimization of ultrafiltration/diafiltration processes for partially bound impurities | |
| Schwartz | Diafiltration for desalting or buffer exchange | |
| US20060131236A1 (en) | Model for microfiltration of poly-disperse suspensions | |
| Naito | How to sequence and assemble plant genomes | |
| Choi et al. | Isoporous polyvinylidene fluoride membranes with selective skin layers via a thermal-vapor assisted phase separation method for industrial purification applications | |
| Crespo et al. | Use of fluorescence labelling to monitor protein fractionation by ultrafiltration under controlled permeate flux | |
| Kuriyel et al. | Sterile filtration and virus filtration | |
| Schratter | Purification and concentration by ultrafiltration | |
| JP5312799B2 (ja) | 収集精密ろ過における剪断保護剤 | |
| JP2002543418A (ja) | 流体操作、サーモサイクリング、及び精製を一体化した迅速なｄｎａサンプル処理装置 | |
| Zumstein | Dialysis and ultrafiltration | |
| JP2006343220A (ja) | 生体成分含有溶液の前処理方法および分析溶液精製方法 | |
| Czermak et al. | Membrane filtration in animal cell culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100813 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110809 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120626 |